This page shows the latest rare disease news and features for those working in and with pharma, biotech and healthcare.
Rare disease specialist Shire issued its own statement, noting that Takeda had made three approaches, starting with a £41bn overture on 29 March and followed by a £43bn bid on 11
The FDA gave the go-ahead to a pair of rare disease therapies this week, both marking the first-ever approvals for developers Rigel Pharmaceuticals and Ultragenyx. ... patients. He’s predicting sales could reach $336m in 2022. Ultragenyx has also
In the last few weeks Sanofi has sold its European generics business to Advent, GlaxoSmithKline divested its rare disease unit to start-up Orchard Therapeutics after buying Novartis out of a
The restructuring has already seen it bolster its pipeline in rare diseases with the acquisitions of Bioverativ for $11.6bn and Ablynx for 3.9bn after missing out on earlier bids ... Just this month, for example, GlaxoSmithKline divested its rare disease
GSK hands rare disease assets over to Orchard. The UK pharma group will take a 19.9% stake in its ex-rival. ... GlaxoSmithKline has decided the future of its rare disease business - and it lies outside the company.
Alexion adds to pipeline rebuild with $855m Wilson buy. Also acquires the Swedish group’s lead product for Wilson’s disease. ... Alexion Pharma’s drive to reduce its reliance on cash cow Soliris has gone up a gear with a $855m offer for rare
More from news
Approximately 9 fully matching, plus 328 partially matching documents found.
Accelerating diagnosis in rare disease. Timely diagnosis in rare disease is one of the fundamental unmet needs for patients, healthcare professionals (HCPs) and biopharma. ... However, as referring and prescribing doctors in rare disease can be small in
Accelerating diagnosis in rare disease. Timely diagnosis in rare disease is one of the fundamental unmet needs for patients, healthcare professionals (HCPs) and biopharma. ... However, as referring and prescribing doctors in rare disease can be small in
ALIS (Amikacin liposome inhalation suspension) is being developed as a treatment for refractory non tuberculous Mycobacterial (NTM) lung disease, a rare progressive, destructive infection caused by mycobacterium avium complex. ... NTM is a rare
Rare blood disease products in vogue - Sanofi part 2. In the early part of January it was made public that Novo Nordisk had made an unsolicited $3.1bn (28 per share) ... Sanofi was also interested in caplacizumab, which fits not only with its rare
promise around treating rare diseases. ... However, there is still high unmet need: fewer than one in ten patients with a rare condition receive disease-specific treatment and approved medicines are available for only 5% of rare
More from intelligence
Approximately 1 fully matching, plus 70 partially matching documents found.
Rare genetic disease focused biopharma Abeona Therapeutics has named its chief executive officer in the form of Carsten Thiel. ... Steven Rouhandeh, executive chairman of Abeona, said: “As CEO, Carsten Thiel brings a unique combination of extensive
Williams has more than 25 years’experience in healthcare and pharmaceuticals and most recently he served as vice president and global strategy head for rare gastrointestinal diseases at Shire. ... Commenting on the recent appointment, Luca Santarelli,
Open Health creates new role. Gavin Jones joins the agency as its director of rare disease. ... In order to strengthen their experience and expertise, healthcare communications and market access group Open Health has appointed Gavin Jones into its newly
rare disease commercial infrastructure. ... In this role, Hughes-Wilson was responsible for Sobi’s commercialisation approach and led pricing, reimbursement and access teams for the group’s rare disease product portfolio.
Amryt Pharma appoints new regulatory affairs head. Derval O’Carroll joins the rare disease-focused biopharma from Retrophin. ... Prior to joining Amryt, she served as senior director of regulatory affairs for rare disease group Retrophin.
More from appointments
Approximately 0 fully matching, plus 28 partially matching documents found.
disease.Advances in technology have since allowed us to obtain genomic data easily and affordably. ... There are more than 5, 000 rare genetic diseases, which each show immense clinical variation.
Initiatives such as Rare Disease Day aim to raise awareness of these unusual disorders. ... Want to find out more? Visit the Rare Disease Day website at: www.rarediseaseday.org.
Addressing the biggest challenges for rare disease communities. Each year, Rare Disease Day takes place worldwide on the last day in February. ... For more information about specific challenges for the rare disease communities, please read our full
PEGASUS WINS COMMUNIQUÉ 2015 ‘ EXCELLENCE IN PATIENT/CONSUMER HEALTH PROGRAMMES’ AWARD FOR RARE DISEASE AWARENESS CAMPAIGN. ... Paul Dixon, Head of Marketing UK &Ireland, CSL Behring UK Ltd, commented: “ The results of the campaign were
In addressing that challenge, a first question is whether the term rare disease is too broad. ... When considering rare disease in particular diagnosis is frequently a long drawn-out process.
More from PMHub
Approximately 6 fully matching, plus 9 partially matching documents found.
Independent healthcare communications agency with a passion to develop inspirational ideas that create sustained and positive change. Whether it is...